Travoprost.
Travoprost is a synthetic ester prodrug of a prostaglandin F(2alpha) analogue used in the treatment of open-angle glaucoma and ocular hypertension. Intraocular travoprost 0.004% once daily was significantly more effective at reducing intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension than placebo or timolol 0.5% twice daily and was at least as effective as latanoprost 0.005% once daily in randomised, double-blind studies. When used as adjunctive therapy with timolol 0.5% twice daily in patients with elevated IOP not adequately controlled by timolol alone, travoprost 0.004% showed significant additional IOP reduction in a randomised double-blind trial. Travoprost 0.004% was well tolerated in clinical trials. The majority of adverse events such as ocular hyperaemia and eyelash changes were mild and resolved without treatment.
Waugh
John
J
Adis International Limited, Mairangi Bay, Auckland, New Zealand. demail@adis.co.nz
Jarvis
Blair
B
D000328:Adult; D000368:Aged; D003008:Cloprostenol / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000493:pharmacokinetics / Q000627:therapeutic use; D004334:Drug Administration Schedule; D005902:Glaucoma, Open-Angle / Q000188:drug therapy*; D006207:Half-Life; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D009798:Ocular Hypertension / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D000069557:Travoprost
D003008:Cloprostenol; D000069557:Travoprost